Proteomics

Dataset Information

0

Quantitative phosphoproteomic analysis of acquired drug resistance to pazopanib and dasatinib


ABSTRACT: Acquired drug resistance and tumour relapse impacts the majority of patients being treated with tyrosine kinase inhibitors (TKIs) and remains a key challenge in modern anti-cancer therapy. The lack of clinically effective therapeutic strategies to overcome drug resistance represents a significant unmet need. Understanding the signalling pathways that drive drug resistance will facilitate the development of new salvage therapies to effectively treat patients with secondary TKI resistance. In this study, we utilise quantitative mass spectrometry to characterise the global phosphoproteomic alterations that accompany the acquisition of resistance to two FDA-approved multi-target TKIs, pazopanib and dasatinib, in the A204 rhabdoid tumour cell line. Our analysis finds that only a limited fraction of the quantified phosphoproteome (<10%) is altered upon the acquisition of drug resistance with pazopanib resistant cells displaying elevated phosphorylation levels in cytoskeletal regulatory pathways and dasatinib resistant cells showing an upregulation of components of the insulin receptor/IGF1-R signalling pathway. Drug response profiling with a targeted panel of small molecule inhibitors rediscovers several previously reported vulnerabilities associated with pazopanib and dasatinib resistance and identifies a new dependency to the second generation HSP90 inhibitor NVP-AUY-922. This study provides a useful resource detailing the candidate signalling determinants of acquired TKI resistance; and reveals a therapeutic approach of inhibiting HSP90 function as a means of salvage therapy to overcome pazopanib and dasatinib resistance.

INSTRUMENT(S): LTQ Orbitrap Velos, Q Exactive

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Permanent Cell Line Cell, Cell Culture

DISEASE(S): Rhabdoid Cancer

SUBMITTER: Frank McCarthy  

LAB HEAD: Paul Huang

PROVIDER: PXD005536 | Pride | 2017-08-30

REPOSITORIES: Pride

altmetric image

Publications

Quantitative phosphoproteomic analysis of acquired cancer drug resistance to pazopanib and dasatinib.

Vyse Simon S   McCarthy Frank F   Broncel Malgorzata M   Paul Angela A   Wong Jocelyn P JP   Bhamra Amandeep A   Huang Paul H PH  

Journal of proteomics 20170824


Acquired drug resistance impacts the majority of patients being treated with tyrosine kinase inhibitors (TKIs) and remains a key challenge in modern anti-cancer therapy. The lack of clinically effective therapies to overcome resistance represents an unmet need. Understanding the signalling that drives drug resistance will facilitate the development of new salvage therapies to treat patients with secondary TKI resistance. In this study, we utilise mass spectrometry to characterise the global phos  ...[more]

Similar Datasets

2021-07-20 | PXD019701 | Pride
| E-GEOD-39073 | biostudies-arrayexpress
2013-11-27 | GSE39073 | GEO
2023-08-08 | GSE239677 | GEO
2018-09-18 | GSE97352 | GEO
2022-01-12 | PXD023131 | Pride
2022-02-28 | PXD006167 | Pride
2016-12-21 | PXD005272 | Pride
| E-GEOD-33290 | biostudies-arrayexpress
2016-06-29 | PXD001578 | Pride